BACKGROUND AND AIMS: Ezetimibe was introduced recently as a new class of cholesterol-lowering drugs. Until now only limited increases of transaminase levels were reported. METHODS: We studied 2 patients with severe hepatic side effects of ezetimibe in a general community hospital. RESULTS: Ezetimibe may lead to 2 distinct types of severe hepatic side effects. CONCLUSIONS: Ezetimibe may rarely cause hepatotoxicity, severe cholestatic hepatitis, or acute autoimmune hepatitis.
BACKGROUND AND AIMS: Ezetimibe was introduced recently as a new class of cholesterol-lowering drugs. Until now only limited increases of transaminase levels were reported. METHODS: We studied 2 patients with severe hepatic side effects of ezetimibe in a general community hospital. RESULTS:Ezetimibe may lead to 2 distinct types of severe hepatic side effects. CONCLUSIONS:Ezetimibe may rarely cause hepatotoxicity, severe cholestatic hepatitis, or acute autoimmune hepatitis.
Authors: Christine R Kovach; Diana Lynn Woods; Elizabeth C Devine; Brent R Logan; Hershel Raff Journal: Res Gerontol Nurs Date: 2013-10-24 Impact factor: 1.571
Authors: Jelani K Grant; Sarah Snow; Michelle Kelsey; Jennifer Rymer; Anna E Schaffer; Manesh R Patel; Robert W McGarrah; Neha J Pagidipati; Nishant P Shah Journal: Curr Cardiol Rep Date: 2022-07-29 Impact factor: 3.955
Authors: Morteza Enajat; Steven Teerenstra; Janet T van Kuilenburg; Aty H N van Sorge-Greve; Marjo T H Albers-Akkers; Freek W A Verheugt; Gheorghe A M Pop Journal: Drugs Aging Date: 2009 Impact factor: 3.923